Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Anton Hagenbeek

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Delaloye Angelika Bischof; Antonescu Cristian; Louton Thomas; Kuhlmann Jens; Hagenbeek Anton
Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
van Meerten T; Hagenbeek A
CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
Hagenbeek Anton; Gascoyne Randy D; Dreyling Martin; Kluin Philip; Engert Andreas; Salles Gilles
Biomarkers and prognosis in malignant lymphomas.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Anton Hagenbeek (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Delaloye Angelika Bischof; Antonescu Cristian; Louton Thomas; Kuhlmann Jens; Hagenbeek Anton
Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(11):1837-43.
2009: van Meerten T; Hagenbeek A
CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
The Netherlands journal of medicine 2009;67(7):251-9.
2009: Hagenbeek Anton; Gascoyne Randy D; Dreyling Martin; Kluin Philip; Engert Andreas; Salles Gilles
Biomarkers and prognosis in malignant lymphomas.
Clinical lymphoma & myeloma 2009;9(2):160-6.
2009: Hagenbeek Anton
Maintenance or eradication of residual disease in indolent lymphoma: where do we stand?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(10):1540-2.
2009: van 't Veer Mars B; de Jong Daphne; MacKenzie Marius; Kluin-Nelemans Hanneke C; van Oers Marinus H J; Zijlstra Jose; Hagenbeek Anton; van Putten Wim L J
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
British journal of haematology 2009;144(4):524-30.
2009: de Jong D; Xie W; Rosenwald A; Chhanabhai M; Gaulard P; Klapper W; Lee A; Sander B; Thorns C; Campo E; Molina T; Hagenbeek A; Horning S; Lister A; Raemaekers J; Salles G; Gascoyne R D; Weller E
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium).
Journal of clinical pathology 2009;62(2):128-38.
2009: de Jong Daphne; Koster Ad; Hagenbeek Anton; Raemaekers John; Veldhuizen Dennis; Heisterkamp Sabien; de Boer Jan Paul; van Glabbeke Martine
Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.
Haematologica 2009;94(1):70-7.
2008: Morschhauser Franck; Radford John; Van Hoof Achiel; Vitolo Umberto; Soubeyran Pierre; Tilly Herve; Huijgens Peter C; Kolstad Arne; d'Amore Francesco; Gonzalez Diaz Marcos; Petrini Mario; Sebban Catherine; Zinzani Pier Luigi; van Oers Marinus H J; van Putten Wim; Bischof-Delaloye Angelika; Rohatiner Ama; Salles Gilles; Kuhlmann Jens; Hagenbeek Anton
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(32):5156-64.
2008: Kapur Rick; Ebeling Saskia; Hagenbeek Anton
B-cell involvement in chronic graft-versus-host disease.
Haematologica 2008;93(11):1702-11.
2008: Hagenbeek Anton; Gadeberg Ole; Johnson Peter; Pedersen Lars Møller; Walewski Jan; Hellmann Andrzej; Link Brian K; Robak Tadeusz; Wojtukiewicz Marek; Pfreundschuh Michael; Kneba Michael; Engert Andreas; Sonneveld Pieter; Flensburg Mimi; Petersen Jørgen; Losic Nedjad; Radford John
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Blood 2008;111(12):5486-95.
2007: de Jong Daphne; Rosenwald Andreas; Chhanabhai Mukesh; Gaulard Philippe; Klapper Wolfram; Lee Abigail; Sander Birgitta; Thorns Christoph; Campo Elias; Molina Thierry; Norton Andrew; Hagenbeek Anton; Horning Sandra; Lister Andrew; Raemaekers John; Gascoyne Randy D; Salles Gilles; Weller Edie;
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):805-12.
2007: Cheson Bruce D; Pfistner Beate; Juweid Malik E; Gascoyne Randy D; Specht Lena; Horning Sandra J; Coiffier Bertrand; Fisher Richard I; Hagenbeek Anton; Zucca Emanuele; Rosen Steven T; Stroobants Sigrid; Lister T Andrew; Hoppe Richard T; Dreyling Martin; Tobinai Kensei; Vose Julie M; Connors Joseph M; Federico Massimo; Diehl Volker;
Revised response criteria for malignant lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):579-86.
2007: Marcus Robert; Hagenbeek Anton
The therapeutic use of rituximab in non-Hodgkin's lymphoma.
European journal of haematology. Supplementum 2007;(67):5-14.
2007: van Rijn Rozemarijn S; Simonetti Elles R; Hagenbeek Anton; Bonyhadi Mark; Storm Gert; Martens Anton C M; Ebeling Saskia B
Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality.
Experimental hematology 2007;35(1):117-27.
2006: van Oers Marinus H J; Klasa Richard; Marcus Robert E; Wolf Max; Kimby Eva; Gascoyne Randy D; Jack Andrew; Van't Veer Mars; Vranovsky Andrej; Holte Harald; van Glabbeke Martine; Teodorovic Ivana; Rozewicz Cynthia; Hagenbeek Anton
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.
Blood 2006;108(10):3295-301.
2006: van Meerten Tom; van Rijn Rozemarijn S; Hol Samantha; Hagenbeek Anton; Ebeling Saskia B
Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):4027-35.
2006: Noordijk Evert M; Carde Patrice; Dupouy Noëlle; Hagenbeek Anton; Krol Augustinus D G; Kluin-Nelemans Johanna C; Tirelli Umberto; Monconduit Mathieu; Thomas José; Eghbali Houchingue; Aleman Berthe M P; Bosq Jacques; Vovk Marjeta; Verschueren Tom A M; Pény Anne-Marie; Girinsky Théodore; Raemaekers John M M; Henry-Amar Michel
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3128-35.
2006: van Meerten T; Claessen M-J; Hagenbeek A; Ebeling S B
The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells.
Gene therapy 2006;13(9):789-97.
2006: Hagenbeek Anton; Eghbali Houchingue; Monfardini Silvio; Vitolo Umberto; Hoskin Peter J; de Wolf-Peeters Christiane; MacLennan Ken; Staab-Renner Elvira; Kalmus Joachim; Schott Astrid; Teodorovic Ivana; Negrouk Anastassia; van Glabbeke Martine; Marcus Robert
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1590-6.
2006: Ivanov Roman; Hagenbeek Anton; Ebeling Saskia
Towards immunogene therapy of hematological malignancies.
Experimental hematology 2006;34(3):251-63.
2006: Ivanov R; Hol S; Aarts T I; Hagenbeek A; Ebeling S B
T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.
Clinical and experimental immunology 2006;143(1):78-84.
2005: van Agthoven Michel; Kramer Mark H H; Sonneveld Pieter; van der Hem Klaas G; Huijgens Peter C; Wijermans Pierre W; Kluin-Nelemans Hanneke C; Schaafsma M Ronald; Biesma Douwe H; Mattijssen Vera; Uyl-de Groot Carin A; Hagenbeek Anton
Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
Haematologica 2005;90(10):1422-32.
2005: Ivanov Roman; Hol Samantha; Aarts Tineke; Hagenbeek Anton; Slager Elisabeth H; Ebeling Saskia
UTY-specific TCR-transfer generates potential graft-versus-leukaemia effector T cells.
British journal of haematology 2005;129(3):392-402.
2005: Hagenbeek A; Lewington V
Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(5):786-92.
2005: Rohatiner A Z S; Gregory W M; Peterson B; Borden E; Solal-Celigny P; Hagenbeek A; Fisher R I; Unterhalt M; Arranz R; Chisesi T; Aviles A; Lister T A
Meta-analysis to evaluate the role of interferon in follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2215-23.
2005: Ivanov Roman; Aarts Tineke; Hol Samantha; Doornenbal Angeline; Hagenbeek Anton; Petersen Eefke; Ebeling Saskia
Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1694-703.
2005: Hagenbeek Anton
Future trends in radioimmunotherapy.
Seminars in oncology 2005;32(1 Suppl 1):S57-62.
2005: Ivanov R; Aarts T; Hagenbeek A; Hol S; Ebeling S
B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC.
Cytotherapy 2005;7(1):62-73.
2004: van Agthoven Michel; Uyl-de Groot Carin A; Sonneveld Pieter; Hagenbeek Anton
Economic assessment in the management of non-Hodgkin's lymphoma.
Expert opinion on pharmacotherapy 2004;5(12):2529-48.
2004: Rozemuller Henk; Knaän-Shanzer Shosh; Hagenbeek Anton; van Bloois Louis; Storm Gert; Martens Anton C M
Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes.
Experimental hematology 2004;32(11):1118-25.
2004: Weijtens Mo; van Spronsen Anke; Hagenbeek Anton; de Weger Roel; Martens Anton
Ganciclovir-mediated elimination of HSV-Tk+ T cells and cure of graft-vs-host disease in an allogeneic bone marrow transplantation model in the rat.
Experimental hematology 2004;32(10):962-9.
2004: Otten H G; van Ginkel W G J; Hagenbeek A; Petersen E J
Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(8):1401-5.
2004: Kruyt M C; Stijns M M C; Fedorovich N E; De Bruijn J D; Van Blitterswijk C A; Verbout A J; Rozemuller H; Hagenbeek A; Dhert W J A; Martens A C M
Genetic marking with the DeltaLNGFR-gene for tracing goat cells in bone tissue engineering.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2004;22(4):697-702.
2004: van de Donk N W C J; de Weerdt O; Veth G; Eurelings M; van Stralen E; Frankel S R; Hagenbeek A; Bloem A C; Lokhorst H M
G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(6):1078-84.
2004: Kersten Marie José; Jong Dd Daphne de; Raemaekers John M M; Kluin Philip M; Hagenbeek Anton
Beyond the International Prognostic Index: new prognostic factors in follicular lymphoma and diffuse large-cell lymphoma A meeting report of the Second International Lunenburg Lymphoma Workshop.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(3):202-8.
2003: Ebeling S B; Simonetti E R; Borst H P E; Blok A; Schelen A M; Braakman E; Ederveen J; Hagenbeek A
Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious.
Gene therapy 2003;10(21):1800-6.
2003: van Rijn Rozemarijn S; Simonetti Elles R; Hagenbeek Anton; Hogenes Marieke C H; de Weger Roel A; Canninga-van Dijk Marijke R; Weijer Kees; Spits Hergen; Storm Gert; van Bloois Louis; Rijkers Ger; Martens Anton C M; Ebeling Saskia B
A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.
Blood 2003;102(7):2522-31.
2003: Hagenbeek Anton
Minimal residual disease in lymphoma revisited.
Clinical lymphoma 2003;4(1):9.
2003: Aleman Berthe M P; Raemaekers John M M; Tirelli Umberto; Bortolus Roberto; van 't Veer Mars B; Lybeert Marnix L M; Keuning Jo J; Carde Patrice; Girinsky Théodore; van der Maazen Richard W M; Tomsic Radka; Vovk Marjeta; van Hoof Achilles; Demeestere Geertrui; Lugtenburg Pieternella J; Thomas José; Schroyens Wilfried; De Boeck Koenraad; Baars Johanna W; Kluin-Nelemans Johanna C; Carrie Christian; Aoudjhane Malek; Bron Dominique; Eghbali Houchingue; Smit Wilma G J M; Meerwaldt Jacobus H; Hagenbeek Anton; Pinna Antonella; Henry-Amar Michel;
Involved-field radiotherapy for advanced Hodgkin's lymphoma.
The New England journal of medicine 2003;348(24):2396-406.
2003: Ebeling Saskia B; Ivanov Roman; Hol Samantha; Aarts Tineke I; Hagenbeek Anton; Verdonck Leo F; Petersen Eefke J
HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells.
British journal of haematology 2003;121(5):721-9.
2003: Ebeling Saskia B; Eric Borst H P; Simonetti Elles R; Hol Samantha; Garin Marina I; Slaper-Cortenbach Ineke; Hagenbeek Anton
Development and application of quantitative real time PCR and RT-PCR assays that discriminate between the full-length and truncated herpes simplex virus thymidine kinase gene.
Journal of virological methods 2003;109(2):177-86.
2003: Kolen Sebastianus; Weijtens Mo; Hagenbeek Anton; van Spronsen Anke; Smulders Saskia; de Weger Roel; de Witte Theo; Dolstra Harry; van de Wiel van Kemenade Elly; Martens Anton
Monitoring of developing graft-versus-host disease mediated by herpes simplex virus thymidine kinase gene-transduced T cells.
Human gene therapy 2003;14(4):341-51.
2003: Hagenbeek Anton
Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
Leukemia & lymphoma 2003;44 Suppl 4():S37-47.
2003: Hagenbeek A; Bischof Delaloye A
Editorial perspective--advances in B-cell non-Hodgkin's lymphoma.
Leukemia & lymphoma 2003;44 Suppl 4():S1-4.
2003: van Agthoven Michel; Sonneveld Pieter; Hagenbeek Anton; Uyl-de Groot Carin A
A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma.
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(6):399-409.
2002: Hagenbeek Anton; Czuczman Myron S; Ghielmini Michele; Herold Michael; Kimby Eva; Solal-Céligny Philippe; Unterhalt Michael
Rituximab therapy for indolent non-Hodgkin's lymphoma.
Anti-cancer drugs 2002;13 Suppl 2():S11-7.
2002: Van Oers M H J; Hagenbeek A; Van Glabbeke M; Teodorovic I
Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
Annals of hematology 2002;81(10):553-7.
2002: van Agthoven M; Groot M T; Verdonck L F; Löwenberg B; Schattenberg A V M B; Oudshoorn M; Hagenbeek A; Cornelissen J J; Uyl-de Groot C A; Willemze R
Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia.
Bone marrow transplantation 2002;30(4):243-51.
2002: Weijtens Mo; van Spronsen Anke; Hagenbeek Anton; Braakman Eric; Martens Anton
Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats.
Human gene therapy 2002;13(2):187-98.
2001: Buijs A; Poddighe P; van Wijk R; van Solinge W; Borst E; Verdonck L; Hagenbeek A; Pearson P; Lokhorst H
A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies.
Blood 2001;98(9):2856-8.
2001: Chalmers D; Ferrand C; Apperley J F; Melo J V; Ebeling S; Newton I; Duperrier A; Hagenbeek A; Garrett E; Tiberghien P; Garin M
Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene.
Molecular therapy : the journal of the American Society of Gene Therapy 2001;4(2):146-8.
2001: de Weerdt O; van de Donk N W; Veth G; Bloem A C; Hagenbeek A; Lokhorst H M
Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma.
The Netherlands journal of medicine 2001;59(2):50-6.
2000: van Leeuwen F E; Klokman W J; Veer M B; Hagenbeek A; Krol A D; Vetter U A; Schaapveld M; van Heerde P; Burgers J M; Somers R; Aleman B M
Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):487-97.
2000: El-Beltagi H M; Martens A C; Hagenbeek A
Leukemia cell lines resistant to cytosine arabinoside, cyclophosphamide or daunomycin are equally sensitive to the drug acetyldinaline as the parental cell line.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(1):213-4.
1999: Braakman E; Vogels R; Martens A C; Vermeulen J; Bron M; Hoogerbrugge P M; Valerio D; Hagenbeek A
Ganciclovir-mediated in vivo elimination of myeloid leukemic cells expressing the HSVtk gene induces HSVtk loss variants.
Gene therapy 1999;6(6):1139-46.
1999: Vellenga E; van Putten W L; Boogaerts M A; Daenen S M; Verhoef G E; Hagenbeek A; Jonkhoff A R; Huijgens P C; Verdonck L F; van der Lelie J; Schouten H C; Gmür J; Wijermans P; Gratwohl A; Hess U; Fey M F; Löwenberg B
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?
Bone marrow transplantation 1999;23(12):1279-82.
1999: Martens A C; Hagenbeek A
Amifostine (WR2721) for dose escalation in marrow-ablative treatment of leukaemia.
European journal of cancer (Oxford, England : 1990) 1999;35(4):634-40.
1999: Arkesteijn G; Jumelet E; Hagenbeek A; Smit E; Slater R; Martens A
Reverse chromosome painting for the identification of marker chromosomes and complex translocations in leukemia.
Cytometry 1999;35(2):117-24.
1998: Rozemuller H; Terpstra W; Rombouts E J; Lawler M; Byrne C; FitzGerald D J; Kreitman R J; Wielenga J J; Löwenberg B; Touw I P; Hagenbeek A; Martens A C
GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(12):1962-70.
1998: Havenga M J; Vogels R; Braakman E; Kroos N; Valerio D; Hagenbeek A; van Es H H
Second gene expression in bicistronic constructs using short synthetic intercistrons and viral IRES sequences.
Gene 1998;222(2):319-27.
1998: Blay J; Gomez F; Sebban C; Bachelot T; Biron P; Guglielmi C; Hagenbeek A; Somers R; Chauvin F; Philip T
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Blood 1998;92(10):3562-8.
1998: Guglielmi C; Gomez F; Philip T; Hagenbeek A; Martelli M; Sebban C; Milpied N; Bron D; Cahn J Y; Somers R; Sonneveld P; Gisselbrecht C; Van Der Lelie H; Chauvin F
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3264-9.
1998: Rozemuller H; Rombouts E J; Touw I P; FitzGerald D J; Kreitman R J; Hagenbeek A; Martens A C
In vivo targeting of leukemic cells using diphtheria toxin fused to murine GM-CSF.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(5):710-7.
1998: Gowing H; Braakman E; Hagenbeek A; Lawler M; McCann S R; Pamphilon D H; Martens A C
Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
Bone marrow transplantation 1998;21(8):801-7.
1998: Hagenbeek A; Carde P; Meerwaldt J H; Somers R; Thomas J; De Bock R; Raemaekers J M; van Hoof A; De Wolf-Peeters C; van Glabbeke M
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):41-7.
1997: Löwenberg B; Boogaerts M A; Daenen S M; Verhoef G E; Hagenbeek A; Vellenga E; Ossenkoppele G J; Huijgens P C; Verdonck L F; van der Lelie J; Wielenga J J; Schouten H C; Gmür J; Gratwohl A; Hess U; Fey M F; van Putten W L
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(12):3496-506.
1997: Terpstra W; Rozemuller H; Breems D A; Rombouts E J; Prins A; FitzGerald D J; Kreitman R J; Wielenga J J; Ploemacher R E; Löwenberg B; Hagenbeek A; Martens A C
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells.
Blood 1997;90(9):3735-42.
1997: Rozemuller H; Rombouts E J; Touw I P; FitzGerald D J; Kreitman R J; Pastan I; Hagenbeek A; Martens A C
Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein.
British journal of haematology 1997;98(4):952-9.
1997: Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 1():111-4.
1997: Meerwaldt J H; Carde P; Somers R; Thomas J; Kluin-Nelemans J C; Bron D; Noordijk E M; Cosset J M; Bijnens L; Teodorovic I; Hagenbeek A
Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 1():67-70.
1996: Hendrikx P J; Vermeulen J; Hagenbeek A; Vermey M; Martens A C
LacZ staining in paraffin-embedded tissue sections.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1996;44(11):1323-9.
1996: Rozemuller H; Rombouts W J; Touw I P; FitzGerald D J; Kreitman R J; Pastan I; Hagenbeek A; Martens A C
Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(11):1796-803.
1996: Pittaluga S; Bijnens L; Teodorovic I; Hagenbeek A; Meerwaldt J H; Somers R; Thomas J; Noordijk E M; De Wolf-Peeters C
Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation.
Blood 1996;87(10):4358-67.
1996: Arkesteijn G J; Erpelinck S L; Martens A C; Hagemeijer A; Hagenbeek A
The use of FISH with chromosome-specific repetitive DNA probes for the follow-up of leukemia patients. Correlations and discrepancies with bone marrow cytology.
Cancer genetics and cytogenetics 1996;88(1):69-75.
1996: Hendrikx P J; Martens C M; Hagenbeek A; Keij J F; Visser J W
Homing of fluorescently labeled murine hematopoietic stem cells.
Experimental hematology 1996;24(2):129-40.
1996: O'Neill P A; Lawler M; Pullens R; Kloosterman T; Hudson J; Martens A C; Hendrikx P J; Gowing H; Byrne C; Hagenbeek A; Pamphilon D H; McCann S R
PCR amplification of short tandem repeat sequences allows serial studies of chimaerism/engraftment following BMT in rodents.
Bone marrow transplantation 1996;17(2):265-71.
1996: Gowing H; Lawler M; Hagenbeek A; McCann S R; Pamphilon D H; Hudson J; van Weelden H; Braakman E; Martens A C
Effect of ultraviolet-B light on lymphocyte activity at doses at which normal bone marrow stem cells are preserved.
Blood 1996;87(4):1635-43.
1995: Teodorovic I; Pittaluga S; Kluin-Nelemans J C; Meerwaldt J H; Hagenbeek A; van Glabbeke M; Somers R; Bijnens L; Noordijk E M; Peeters C D
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2819-26.
1995: Hendrikx P J; Martens A C; Schultz F W; Visser J W; Hagenbeek A
Monitoring of leukemia growth in a rat model using a highly sensitive assay for the detection of LacZ marked leukemic cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(11):1954-60.
1995: Uyl-de Groot C A; Hagenbeek A; Verdonck L F; Löwenberg B; Rutten F F
Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
Bone marrow transplantation 1995;16(3):463-70.
1995: Arkesteijn G J; Erpelinck S L; Martens A C; Hagenbeek A
Chromosome specific DNA hybridization in suspension for flow cytometric detection of chimerism in bone marrow transplantation and leukemia.
Cytometry 1995;19(4):353-60.
1995: Uyl-de Groot C A; Okhuijsen S Y; Hagenbeek A; Huijgens P C; van Imhoff G W; Löwenberg B; Verdonck L F; Rutten F F
Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands.
Bone marrow transplantation 1995;15(4):605-10.
1995: Kloosterman T C; Martens A C; van Bekkum D W; Hagenbeek A
Graft-versus-leukemia in rat MHC-mismatched bone marrow transplantation is merely an allogeneic effect.
Bone marrow transplantation 1995;15(4):583-90.
1994: Kloosterman T C; Martens A C; Osterwalder B; Hagenbeek A
Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML.
Bone marrow transplantation 1994;14(6):965-73.
1994: Hendrikx P J; Martens A C; Visser J W; Hagenbeek A
Differential suppression of background mammalian lysosomal beta-galactosidase increases the detection sensitivity of LacZ-marked leukemic cells.
Analytical biochemistry 1994;222(2):456-60.
1994: Kloosterman T C; Tielemans M J; Martens A C; van Bekkum D W; Hagenbeek A
Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia.
Bone marrow transplantation 1994;14(1):15-22.
1994: de Groot C J; Martens A C; Hagenbeek A
Aldehyde dehydrogenase involvement in a variant of the brown Norway rat acute myelocytic leukaemia (BNML) that acquired cyclophosphamide resistance in vivo.
European journal of cancer (Oxford, England : 1990) 1994;30A(14):2137-43.
1993: el-Beltagi H M; Martens A C; Dahab G M; Hagenbeek A
Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): preclinical studies in the BNML rat model for human acute myelocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(11):1795-800.
1993: Carde P; Hagenbeek A; Hayat M; Monconduit M; Thomas J; Burgers M J; Noordijk E M; Tanguy A; Meerwaldt J H; Le Fur R
Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2258-72.
1993: el-Beltagi H M; Martens A C; Haroun E A; Hagenbeek A
In vivo development of an acetyldinaline resistant subline of the BN rat acute myelocytic leukemia (BNML).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(8):1275-80.
1993: el-Beltagi H M; Martens A C; Lelieveld P; Haroun E A; Hagenbeek A
Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia.
Cancer research 1993;53(13):3008-14.
1993: Gaiser J F; Kloosterman T C; Martens A C; Hagenbeek A
In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(5):736-41.
1993: Yan Y; Martens A C; de Groot C J; Hendrikx P J; Valerio D; van Bekkum D W; Hagenbeek A
Retrovirus-mediated transfer and expression of marker genes in the BN rat acute myelocytic leukemia model for the study of minimal residual disease (MRD).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(1):131-9.
1992: Hagenbeek A
Leukemic cell kill in autologous bone marrow transplantation: in vivo or in vitro?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 4():85-7.
1992: Kloosterman T C; Tielemans M J; Martens A C; Hoogerbrugge P M; van Bekkum D W; Hagenbeek A
L4415: further characterization of the rat model for human acute lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(11):1161-6.
1992: Hagenbeek A
Minimal residual disease in leukemia: state of the art 1991.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():12-6.
1991: Martens A C; de Groot C J; Hagenbeek A
Development and characterisation of a cyclophosphamide resistant variant of the BNML rat model for acute myelocytic leukaemia.
European journal of cancer (Oxford, England : 1990) 1991;27(2):161-6.
1990: Ruit J B; Löwenberg B; Hagenbeek A; Verhoef G E; Wielenga J J; Michiels J; Sizoo W
Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.
Seminars in oncology 1990;17(6 Suppl 10):24-7.
1990: Hagenbeek A; Martens A C; Schultz F W; van Bekkum D W
Cure after allogeneic bone marrow transplantation: chemo-radiotherapy and/or graft-versus-leukemia?
Bone marrow transplantation 1990;6 Suppl 1():91-3.
1990: Martens A C; Van Bekkum D W; Hagenbeek A
The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(4):241-57.
1990: Arkesteijn G J; van Dekken H; Martens A C; Hagenbeek A
Clinical applications of flow karyotyping in myelocytic leukemia by stimulation of different subpopulations of cells in blood or bone marrow samples.
Cytometry 1990;11(1):196-201.
1990: Nooter K; de Vries A; Martens A C; Hagenbeek A
Effect of cyclophosphamide pretreatment on daunorubicin in rat acute leukaemia model.
European journal of cancer (Oxford, England : 1990) 1990;26(6):729-32.
1989: Hagenbeek A; Martens A C
Minimal residual disease in acute leukemia: from experimental models to man.
Bone marrow transplantation 1989;4 Suppl 3():68-9.
1989: van Dekken H; Hagenbeek A; Bauman J G
Detection of host cells following sex-mismatched bone marrow transplantation by fluorescent in situ hybridization with a Y-chromosome specific probe.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(10):724-8.
1989: Hagenbeek A; Martens A C
Cryopreservation of autologous marrow grafts in acute leukemia: survival of in vivo clonogenic leukemic cells and normal hemopoietic stem cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(7):535-7.
1989: Schultz F W; Martens A C; Hagenbeek A
The contribution of residual leukemic cells in the graft to leukemia relapse after autologous bone marrow transplantation: mathematical considerations.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(7):530-4.
1989: Hagenbeek A; Martens A C
On the heterogeneity of minimal residual disease in acute leukemia.
Bone marrow transplantation 1989;4 Suppl 1():9-12.
1988: Schouten H C; Sizoo W; van 't Veer M B; Hagenbeek A; Löwenberg B
Incomplete chimerism in erythroid, myeloid and B lymphocyte lineage after T cell-depleted allogeneic bone marrow transplantation.
Bone marrow transplantation 1988;3(5):407-12.
1988: Arkesteijn G J; Martens A C; Hagenbeek A
Bivariate flow karyotyping in human Philadelphia-positive chronic myelocytic leukemia.
Blood 1988;72(1):282-6.
1988: Hagenbeek A; Weiershausen U; Martens A C
Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1988;2(4):226-30.
1988: Carde P; Hayat M; Cosset J M; Somers R; Burgers J M; Sizoo W; Meerwaldt J H; Hagenbeek A; Monconduit M; van der Schueren E
Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin's disease: experience of the European Organization for Research and Treatment of Cancer.
NCI monographs : a publication of the National Cancer Institute 1988;(6):303-10.
1987: Arkesteijn G J; Martens A C; Jonker R R; Hagemeijer A; Hagenbeek A
Bivariate flow karyotyping of acute myelocytic leukemia in the BNML rat model.
Cytometry 1987;8(6):618-24.
1987: Martens A C; Schultz F W; Hagenbeek A
Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease.
Blood 1987;70(4):1073-8.
1986: Löwenberg B; Wagemaker G; van Bekkum D W; Sizoo W; Sintnicolaas K; Hendriks W D; Hagenbeek A
Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors.
Bone marrow transplantation 1986;1(2):133-40.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Anton Hagenbeek

Research Profile (preview)

Living Beings

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Anton Hagenbeek (preview)

All Publications